Patents by Inventor Mario Saltarelli

Mario Saltarelli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination of dopamine agonists and aralkyl and aralkylidene heterocyclic lactams and imides
    Publication number: 20060052373
    Abstract: The present invention relates to a pharmaceutical composition containing (i) a dopamine agonist or a pharmaceutically acceptable salt thereof, (ii) a compound of the formula I as defined in the specification, and optionally (iii) a pharmaceutically acceptable carrier, and to their medicinal use. These compositions are useful as psychotherapeutic agents.
    Type: Application
    Filed: November 17, 2004
    Publication date: March 9, 2006
    Inventors: Paul Glue, Gerard Marek, Mario Saltarelli
  • Nicotinic acetylcholine receptor antagonists in the treatment of restless legs syndrome
    Publication number: 20050250806
    Abstract: This invention relates to the use of nicotinic acetylcholine receptor agonists for the treatment of restless legs syndrome (RLS). The invention further relates to the use of a nicotinic acetylcholine receptor agonist in the manufacture of a medicament for the treatment of RLS. The present invention also relates to a pharmaceutical composition for the treatment of RLS containing a nicotinic acetylcholine receptor agonist.
    Type: Application
    Filed: July 13, 2005
    Publication date: November 10, 2005
    Inventor: Mario Saltarelli
  • Combination of dopamine agonists and monoamine reuptake inhibitors
    Publication number: 20050250803
    Abstract: This invention is directed to pharmaceutical compositions and kits comprising (i) a dopamine agonist of the formula II as described in the specification, (ii) a monoamine reuptake inhibitor or pharmaceutically acceptable salt thereof; and optionally (iii) a pharmaceutically acceptable carrier. This invention further relates to methods of treatment using those pharmaceutical compositions.
    Type: Application
    Filed: November 17, 2004
    Publication date: November 10, 2005
    Inventors: Paul Glue, Mario Saltarelli, Gerard Marek
  • NMDA NR2B antagonists for treatment
    Patent number: 6958351
    Abstract: The invention provides new methods for treating certain disorders resulting from neurodegeneration and for treating depression which comprise administration of NR2B subunit selective NMDA antagonists. The disorders that can be treating by the invention include hearing loss, vision loss, neurodegeneration caused by epileptic seizures, neurotoxin poisoning, Restless Leg Syndrome, multi-system atrophy, non-vascular headache, and depression.
    Type: Grant
    Filed: October 2, 2001
    Date of Patent: October 25, 2005
    Assignee: Pfizer Inc
    Inventors: Bertrand L. Chenard, Mario Saltarelli, Frank S. Menniti